Skip to main content

Table 1 Hemodynamic measurements

From: Neuroprotective effects of amiodarone in a mouse model of ischemic stroke

Group   SBP DBP HR
(mmHg) (mmHg) (beats/min)
Control -1 h (Baseline) 109 ± 6 64 ± 6 469 ± 10
0 h (MCAO) 106 ± 7 63 ± 6 470 ± 14
1 h 124 ± 5 62 ± 8 526 ± 24
48 h 116 ± 7 63 ± 11 490 ± 15
Amiodarone Pre-treatment -1 h (Baseline) 107 ± 8 64 ± 5 477 ± 11
0 h (MCAO) 102 ± 9 60 ± 7 382 ± 23*
1 h 119 ± 8 60 ± 8 444 ± 28*
48 h 113 ± 6 64 ± 7 450 ± 22*
Amiodarone Post-treatment -1 h (Baseline) 108 ± 6 63 ± 5 474 ± 17
0 h (MCAO) 109 ± 7 63 ± 6 471 ± 13
1 h 117 ± 11 59 ± 12 416 ± 12*
48 h 116 ± 13 64 ± 8 456 ± 18*
Amiodarone Pre-treatment
+
Veratrine
-1 h (Baseline) 110 ± 9 63 ± 7 485 ± 24
0 h (MCAO) 114 ± 11 64 ± 8 424 ± 14*
1 h 119 ± 9 63 ± 7 425 ± 16*
48 h 113 ± 7 68 ± 4 491 ± 23
Amiodarone Pre-treatment
+
Isoproterenol
-1 h (Baseline) 109 ± 8 64 ± 9 465 ± 20
0 h (MCAO) 100 ± 6 58 ± 4 472 ± 16
1 h 110 ± 6 65 ± 4 440 ± 31*
48 h 106 ± 8 64 ± 4 471 ± 37
  1. Heart rate was lower in the amiodarone pre-treatment group, amiodarone post-treatment group, and amiodarone + veratrine group than in the control mice at the time of MCAO
  2. There was a trend toward slightly lower systolic blood pressure and diastolic blood pressure for animals that received 50 mg/kg amiodarone; however, the difference was not statistically significant (*P < 0.05 vs. control)
  3. Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, MCAO middle cerebral artery occlusion